SCHEMBL3358243

SCHEMBL3358243

CC(C)(C)c1ccc(O[SiH3])cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.52
ALDH1A1 P00352 3/20 0.52
RAB9A P51151 3/20 0.52
MAPK1 P28482 2/20 0.52
NPC1 O15118 2/20 0.52
HPGD P15428 1/20 0.52
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
TSHR P16473 1/20 0.48
LMNA P02545 2/20 0.46
TYR P14679 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
TDP1 Q9NUW8 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
APP P05067 1/20 0.42
ALOX15 P16050 1/20 0.41
APEX1 P27695 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21761364 0.84 HPGD (0.46) MAPTALDH1A1RAB9AMAPK1NPC1
SCHEMBL17651618 0.78 MAPK1 (0.34) MAPTALDH1A1RAB9AMAPK1NPC1
SCHEMBL9393171 0.78 NPC1 (0.33) MAPTALDH1A1RAB9AMAPK1NPC1
SCHEMBL127279 0.78 RAB9A (0.77) MAPTALDH1A1RAB9AMAPK1NPC1
SCHEMBL18118972 0.78 RAB9A (0.77) MAPTALDH1A1RAB9AMAPK1NPC1
SCHEMBL427816 0.78 RAB9A (0.77) MAPTALDH1A1RAB9AMAPK1NPC1
SCHEMBL4882852 0.78 MAPT (0.56) MAPTALDH1A1RAB9AMAPK1NPC1
SCHEMBL72636 0.77 TSHR (0.52) MAPTALDH1A1RAB9AMAPK1NPC1
SCHEMBL424728 0.76 TSHR (0.73) MAPTALDH1A1RAB9AMAPK1NPC1
SCHEMBL3822059 0.76 CA12 (0.38) ALDH1A1CA1CA2CA9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3008228-A1 POLARITY REVERSAL ELECTROLYSIS Azad, Abdul R. M. (US) 2016-04-20 EP disclosed
US-20160097134-A1 Conversion of Pharmaceuticals and Chemicals into different Compounds by Polarity Reversal Electrolysis AZAD ABDUL R M (US) 2016-04-07 US disclosed
WO-2014200916-A1 POLARITY REVERSAL ELECTROLYSIS AZAD ABDUL R M (US) 2014-12-18 WO disclosed
US-20100010166-A1 SILANE-TERMINATED PREPOLYMERS AND RELATIVE ADHESIVE SEALANT FORMULATIONS N.P.T. S.R.L. (IT) 2010-01-14 US disclosed
EP-2064256-A1 SILANE-TERMINATED PREPOLYMERS AND RELATIVE ADHESIVE SEALANT FORMULATIONS N.P.T. S.R.L. (IT) 2009-06-03 EP disclosed
CN-101360513-A Biodegradable and thermosensitive poly(organophosphazene) hydrogel, preparation method thereof and use thereof KOREA INST SCI & TECH (KR) 2009-02-04 CN disclosed
WO-2008031895-A1 SILANE-TERMINATED PREPOLYMERS AND RELATIVE ADHESIVE SEALANT FORMULATIONS N.P.T. S.R.L. (IT) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160097134-A1 Conversion of Pharmaceuticals and Chemicals into different Compounds by Polarity Reversal Electrolysis PEF1, CYP11B2, CYP3A4 MAPT 3363/4885ALDH1A1 2847/4885RAB9A 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.